Gilla Kaplan's most recent trade in Avalo Therapeutics Inc was a trade of 20,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Sale of securities on an exchange or to another person at price $ 9.78 per share. | 17 Jun 2025 | 9,568 | 28,231 | - | 9.8 | 93,596 | Common Stock |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Sale of securities on an exchange or to another person at price $ 10.40 per share. | 17 Jun 2025 | 10 | 37,799 | - | 10.4 | 104 | Common Stock |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Sale of securities on an exchange or to another person at price $ 10.31 per share. | 12 Jun 2025 | 30,000 | 59,623 | - | 10.3 | 309,255 | Common Stock |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Sale of securities on an exchange or to another person at price $ 10.31 per share. | 12 Jun 2025 | 15,000 | 44,623 | - | 10.3 | 154,583 | Common Stock |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Sale of securities on an exchange or to another person at price $ 10.38 per share. | 12 Jun 2025 | 6,814 | 37,809 | - | 10.4 | 70,726 | Common Stock |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 22,200 | 22,200 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 61,392 | 0 | - | - | Stock Option (Right to Buy) | |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.61 per share. | 13 Jun 2024 | 61,392 | 89,623 | - | 0.6 | 37,449 | Common Stock |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 18,600 | 18,600 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2023 | 3,334 | 3,334 | - | - | Stock Option (Right to Buy) | |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 14,500 | 14,500 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 3,080 | 3,080 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 44,115 | 44,115 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 14,500 | 14,500 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 30,359 | 30,359 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 9,541 | 9,541 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 6,353 | 6,353 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 7,650 | 7,650 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) |